Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis

European Respiratory Journal

Volumn 44, Issue 2, 2014, Pages 394-404

  Ringholz, Fiona C ^a   Buchanan, Paul J ^a   Clarke, Donna T ^a   Millar, Roisin G ^a   McDermott, Michael ^b   Linnane, Barry ^a,c,d   Harvey, Brian J ^e   McNally, Paul ^a,b   Urbach, Valerie ^a,f  

^a National Children's Research Centre   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^d UNIVERSITY OF LIMERICK   (Ireland)

^e BEAUMONT HOSPITAL   (Ireland)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

15 LIPOXYGENASE 2; LEUKOTRIENE B4; LIPOXIN A; OXYGENASE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ARACHIDONATE 15 LIPOXYGENASE; LEUKOTRIENE A4; LIPOXIN;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN CELL; LUNG LAVAGE; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; BLOOD; CHEMISTRY; CYTOLOGY; IMMUNOLOGY; INFLAMMATION; LONGITUDINAL STUDY; LUNG; LUNG ALVEOLUS MACROPHAGE; LUNG DISEASE; METABOLISM; MICROBIOLOGY; NEUTROPHIL; PATHOLOGY; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ANTI-BACTERIAL AGENTS; ARACHIDONATE 15-LIPOXYGENASE; BRONCHOALVEOLAR LAVAGE FLUID; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; INFLAMMATION; LEUKOTRIENE A4; LEUKOTRIENE B4; LIPOXINS; LONGITUDINAL STUDIES; LUNG; LUNG DISEASES; MACROPHAGES, ALVEOLAR; MALE; NEUTROPHILS;

EID: 84905657036     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00106013     Document Type: Article

References (50)

1. Levy BD, Clish CB, Schmidt B, et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001; 2: 612-619. (Pubitemid 32677628)
2. Haeggström JZ, Funk CD. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev 2011; 111: 5866-5898.
3. Mukaida N, Okamoto S, Ishikawa Y, et al. Molecular mechanism of interleukin-8 gene expression. J Leukoc Biol 1994; 56: 554-558. (Pubitemid 24348811)
4. Greally P, Hussein MJ, Cook AJ, et al. Sputum tumour necrosis factor-α and leukotriene concentrations in cystic fibrosis. Arch Dis Child 1993; 68: 389-392. (Pubitemid 23084593)
5. Kim JS, Okamoto K, Rubin BK. Pulmonary function is negatively correlated with sputum inflammatory markers and cough clearability in subjects with cystic fibrosis but not those with chronic bronchitis. Chest 2006; 129: 1148-1154.
6. Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 1984; 81: 5335-5339. (Pubitemid 14048742)
7. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8: 349-361. (Pubitemid 351595216)
8. Bonnans C, Fukunaga K, Levy MA, et al. Lipoxin A4 regulates bronchial epithelial cell responses to acid injury. Am J Pathol 2006; 168: 1064-1072.
9. Colgan SP, Serhan CN, Parkos CA, et al. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J Clin Invest 1993; 92: 75-82. (Pubitemid 23208982)
10. Takano T, Clish CB, Gronert K, et al. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J Clin Invest 1998; 101: 819-826. (Pubitemid 28096079)
11. József L, Zouki C, Petasis NA, et al. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-κB and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci USA 2002; 99: 13266-13271.
12. Bonnans C, Gras D, Chavis C, et al. Synthesis and anti-inflammatory effect of lipoxins in human airway epithelial cells. Biomed Pharmacother 2007; 61: 261-267. (Pubitemid 46891725)
13. Gewirtz AT, McCormick B, Neish AS, et al. Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogs. J Clin Invest 1998; 101: 1860-1869. (Pubitemid 28226104)
14. Karp CL, Flick LM, Park KW, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004; 5: 388-392. (Pubitemid 38500087)
15. Grumbach Y, Quynh NV, Chiron R, et al. LXA4 stimulates ZO-1 expression and transepithelial electrical resistance in human airway epithelial (16HBE14o-) cells. Am J Physiol Lung Cell Mol Physiol 2009; 296: L101-L108.
16. Bonnans C, Mainprice B, Chanez P, et al. Lipoxin A4 stimulates a cytosolic Ca2+ increase in human bronchial epithelium. J Biol Chem 2003; 278: 10879-10884. (Pubitemid 36792632)
17. Verrière V, Higgins G, Al-Alawi M, et al. Lipoxin A4 stimulates calcium-activated chloride currents and increases airway surface liquid height in normal and cystic fibrosis airway epithelia. PLoS One 2012; 7: e37746.
18. Starosta V, Ratjen F, Rietschel E, et al. Anti-inflammatory cytokines in cystic fibrosis lung disease. Eur Respir J 2006; 28: 581-587. (Pubitemid 44794674)
19. Chavis C, Vachier I, Chanez P, et al. 5(S),15(S)- dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors. J Exp Med 1996; 183: 1633-1643.
20. Serhan CN, Hirsch U, Palmblad J, et al. Formation of lipoxin A by granulocytes from eosinophilic donors. FEBS Lett 1987; 217: 242-246. (Pubitemid 17086752)
21. Levy BD, Romano M, Chapman HA, et al. Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J Clin Invest 1993; 92: 1572-1579. (Pubitemid 23273940)
22. Clària J, Lee MH, Serhan CN. Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol Med 1996; 2: 583-596.
23. Special Issue: The lipoxins and the aspirin-triggered lipoxins. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 139-322.
24. Fiore S, Serhan CN. Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J Exp Med 1990; 172: 1451-1457. (Pubitemid 20366221)
25. Bergsson G, Reeves EP, McNally P, et al. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J Immunol 2009; 183: 543-551.
26. Wright L, Tuder RM, Wang J, et al. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med 1998; 157: 219-229. (Pubitemid 28071286)
27. Shindo K, Koide K, Fukumura M. Platelet-activating factor increases leukotriene B4 release in stimulated alveolar macrophages from asthmatic patients. Eur Respir J 1998; 11: 1098-1104. (Pubitemid 28281029)
28. Woods JW, Coffey MJ, Brock TG, et al. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. J Clin Invest 1995; 95: 2035-2046.
29. Chiron R, Grumbach YY, Quynh NV, et al. Lipoxin A4 and interleukin-8 levels in cystic fibrosis sputum after antibiotherapy. J Cyst Fibros 2008; 7: 463-468.
30. Profita M, Sala A, Riccobono L, et al. 15(S)-HETE modulates LTB4 production and neutrophil chemotaxis in chronic bronchitis. Am J Physiol Cell Physiol 2000; 279: C1249-C1258.
31. Mattoscio D, Evangelista V, De Cristofaro R, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. FASEB J 2010; 24: 3970-3980.
32. Planagumà A, Kazani S, Marigowda G, et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008; 178: 574-582.
33. Vachier I, Bonnans C, Chavis C, et al. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol 2005; 115: 55-60. (Pubitemid 40075421)
34. Bonnans C, Vachier I, Chavis C, et al. Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am J Respir Crit Care Med 2002; 165: 1531-1535. (Pubitemid 34606669)
35. Kazani S, Planaguma A, Ono E, et al. Exhaled breath condensate eicosanoid levels associate with asthma and its severity. J Allergy Clin Immunol 2013; 132: 547-553.
36. Kowal-Bielecka O, Kowal K, Distler O, et al. Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum 2005; 52: 3783-3791. (Pubitemid 41798216)
37. Hong S, Gronert K, Devchand PR, et al. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003; 278: 14677-14687. (Pubitemid 36799790)
38. Mukherjee PK, Marcheselli VL, Serhan CN, et al. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 2004; 101: 8491-8496. (Pubitemid 38736602)
39. Shappell SB, Gupta RA, Manning S, et al. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001; 61: 497-503. (Pubitemid 32128606)
40. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11: 723-737.
41. Nassar GM, Morrow JD, Roberts LJ 2nd, et al. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J Biol Chem 1994; 269: 27631-27634. (Pubitemid 24346597)
42. Conrad DJ, Kuhn H, Mulkins M, et al. Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc Natl Acad Sci USA 1992; 89: 217-221.
43. Regamey N, Tsartsali L, Hilliard TN, et al. Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. Thorax 2012; 67: 164-170.
44. Hajj R, Lesimple P, Nawrocki-Raby B, et al. Human airway surface epithelial regeneration is delayed and abnormal in cystic fibrosis. J Pathol 2007; 211: 340-350. (Pubitemid 46172710)
45. Hsiao HM, Sapinoro RE, Thatcher TH, et al. A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLoS One 2013; 8: e58258.
46. Hartl D, Gaggar A, Bruscia E, et al. Innate immunity in cystic fibrosis lung disease. J Cystic Fibros 2012; 11: 363-382.
47. McNally P, Ervine E, Shields MD, et al. High concentrations of pepsin in bronchoalveolar lavage fluid from children with cystic fibrosis are associated with high interleukin-8 concentrations. Thorax 2011; 66: 140-143.
48. Harris JK, De Groote MA, Sagel SD, et al. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci USA 2007; 104: 20529-20533.
49. Simonin-Le Jeune K, Le Jeune A, Jouneau S, et al. Impaired functions of macrophage from cystic fibrosis patients: CD11b, TLR-5 decrease and sCD14, inflammatory cytokines increase. PLoS One 2013; 8: e75667.
50. Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013; 368: 1963-1970.